Cassava appoints angÉlique bordey, phd, to enhance preclinical program in tsc

As svp, neuroscience, dr. bordey will lead cassava's ongoing research and development efforts dr. bordey to direct the scientific evaluation of simufilam in tsc-related epilepsy,  and potentially additional pipeline indications austin, texas, may 01, 2025 (globe newswire) -- cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (cns) disorders, today announced that angÉlique bordey, phd, has joined the company as senior vice president (svp), neuroscience, while continuing her tenured academic position at yale school of medicine on a part time basis. dr. bordey will be primarily responsible for leading cassava's research and development efforts.
SAVA Ratings Summary
SAVA Quant Ranking